Novo Nordisk has announced a €2.1 billion investment to expand its manufacturing facility in Chartres, France. The expansion aims to increase production capacity for diabetes and obesity treatments, reflecting growing global demand for these therapies.

The investment will create approximately 500 new jobs and enhance the site's capabilities in producing both active pharmaceutical ingredients and finished products. Construction is expected to begin in 2024, with operations ramping up over the following years.

This development underscores Novo Nordisk's commitment to strengthening its European manufacturing footprint and supporting healthcare needs worldwide. For more details, visit the official announcement here.